Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas
An Open Label, Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of Gemcitabine Hydrochloride Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas
Sponsor: InnoPharmax Inc.
This PHASE1 trial investigates Advanced Solid Malignancies and Malignant Lymphomas and is currently completed. InnoPharmax Inc. leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- InnoPharmax Inc.
For direct contact, visit the study record on ClinicalTrials.gov .